HOME >> BIOLOGY >> NEWS
Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible status

Genomatix Software GmbH today announced that it has achieved GeneChip-compatibleTM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip microarray platform and that it has joined Affymetrix GeneChip-compatible Applications Program, which provides customers with a broad spectrum of software solutions for biomedical research and development. As a GeneChip-compatible software provider, Genomatix is committed to seamlessly integrating its entire microarray analysis pipeline with the Affymetrix technology.

The Genomatix line of products which achieved GeneChip-compatibleTM status consists of ChipInspector, ChipInspector TL, ElDorado, GEMS Launcher, and BiblioSphere PathwayEdition. With those products Genomatix provides a broad set of solutions for Affymetrix GeneChip users, including analysis of data from Affymetrix whole-genome tiling and exon arrays.

"We are proud of having met the high standards of Affymetrix and earning GeneChip-compatibleTM status. The tight integration of our microarray analysis pipeline with the Affymetrix platform will stimulate exciting new results in both basic and applied biomedical R&D," said Klaus May, Director of Sales and Marketing at Genomatix. "Especially in conjunction with the new Affymetrix tiling and exon array technology, I expect that our tools will drive far greater understanding of genomic organization and transcriptome regulation."

"Affymetrix is pleased to be working with Genomatix in their efforts to develop advanced tools for analyzing GeneChip data," said Steve Lincoln, vice president of Informatics at Affymetrix. "We are particularly excited to see the emergence of next-generation commercial software which can help bring unprecedented levels of genomic resolution into the hands of applied biomedical researchers."


'"/>

Contact: Klaus May
may@genomatix.de
Genomatix Software GmbH
29-Nov-2005


Page: 1

Related biology news :

1. Genomatix expands operations in North America
2. Application of Genomatix in silico methods reveals novel cancer associated genes
3. Genomatix and Molecular Connections form strategic partnership
4. Genomatix wins BioChance grant worth $1.6 million
5. Genomatix appoints distributor for the growing Chinese market
6. MatBase -- A new transcription factor knowledge base released by Genomatix
7. The Center of Nutrigenomics of the TU Munich licences Genomatix Microarray Analysis Pipeline
8. Bayer HealthCare licenses Genomatix for microarray analysis
9. Genomatix technology facilitates de novo identification of new renal disease associated genes
10. Genomatix partners with Research Instruments Pte Ltd for Singapore, Malaysia and Thailand markets
11. German Microarray Excellence Center integrates Genomatix Chip Analysis Pipeline

Post Your Comments:
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: